ID   MORC3_HUMAN             Reviewed;         939 AA.
AC   Q14149; A8KA92; Q9UEZ2;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   13-JUN-2006, sequence version 3.
DT   18-JUN-2025, entry version 177.
DE   RecName: Full=MORC family CW-type zinc finger protein 3;
DE   AltName: Full=Nuclear matrix protein 2 {ECO:0000303|PubMed:11927593};
DE   AltName: Full=Zinc finger CW-type coiled-coil domain protein 3;
GN   Name=MORC3 {ECO:0000312|HGNC:HGNC:23572};
GN   Synonyms=KIAA0136 {ECO:0000312|HGNC:HGNC:23572}, NXP2
GN   {ECO:0000312|HGNC:HGNC:23572}, ZCWCC3 {ECO:0000312|HGNC:HGNC:23572};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=8590280; DOI=10.1093/dnares/2.4.167;
RA   Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. IV. The
RT   coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 2:167-174(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.-S.,
RA   Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y., Soeda E., Ohki M.,
RA   Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U.,
RA   Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A.,
RA   Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J.,
RA   Shibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K.,
RA   Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G.,
RA   Hornischer K., Brandt P., Scharfe M., Schoen O., Desario A., Reichelt J.,
RA   Kauer G., Bloecker H., Ramser J., Beck A., Klages S., Hennig S.,
RA   Riesselmann L., Dagand E., Wehrmeyer S., Borzym K., Gardiner K.,
RA   Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [4]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=11927593; DOI=10.1074/jbc.m201440200;
RA   Kimura Y., Sakai F., Nakano O., Kisaki O., Sugimoto H., Sawamura T.,
RA   Sadano H., Osumi T.;
RT   "The newly identified human nuclear protein NXP-2 possesses three distinct
RT   domains, the nuclear matrix-binding, RNA-binding, and coiled-coil
RT   domains.";
RL   J. Biol. Chem. 277:20611-20617(2002).
RN   [5]
RP   FUNCTION, INTERACTION WITH TP53 AND PML, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF GLU-35.
RX   PubMed=17332504; DOI=10.1091/mbc.e06-08-0747;
RA   Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H.,
RA   Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.;
RT   "Dynamic regulation of p53 subnuclear localization and senescence by
RT   MORC3.";
RL   Mol. Biol. Cell 18:1701-1709(2007).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-503, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [8]
RP   FUNCTION, SUMOYLATION AT LYS-597; LYS-650; LYS-651; LYS-740 AND LYS-794,
RP   SUBUNIT, INTERACTION WITH PML, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-67; GLY-101; TRP-419; LYS-597; LYS-650; LYS-651; LYS-740 AND LYS-794.
RX   PubMed=20501696; DOI=10.1242/jcs.063586;
RA   Mimura Y., Takahashi K., Kawata K., Akazawa T., Inoue N.;
RT   "Two-step colocalization of MORC3 with PML nuclear bodies.";
RL   J. Cell Sci. 123:2014-2024(2010).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-514; SER-540; SER-560 AND
RP   SER-765, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-650, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [12]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-740, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [13]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-650, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH INFLUENZA A VIRUS PA AND PB1 POLYMERASE
RP   SUBUNITS (MICROBIAL INFECTION).
RX   PubMed=26202233; DOI=10.1128/jvi.01530-15;
RA   Ver L.S., Marcos-Villar L., Landeras-Bueno S., Nieto A., Ortin J.;
RT   "The Cellular Factor NXP2/MORC3 Is a Positive Regulator of Influenza Virus
RT   Multiplication.";
RL   J. Virol. 89:10023-10030(2015).
RN   [15]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-650 AND LYS-651, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH HERPES SIMPLEX VIRUS
RP   1/HHV-1 PROTEIN ICP0 (MICROBIAL INFECTION).
RX   PubMed=27440897; DOI=10.1128/jvi.00621-16;
RA   Sloan E., Orr A., Everett R.D.;
RT   "MORC3, a Component of PML Nuclear Bodies, Has a Role in Restricting Herpes
RT   Simplex Virus 1 and Human Cytomegalovirus.";
RL   J. Virol. 90:8621-8633(2016).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-191; LYS-205; LYS-231; LYS-280;
RP   LYS-293; LYS-555; LYS-597; LYS-650; LYS-651; LYS-794 AND LYS-855, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH HERPES SIMPLEX VIRUS 1 /HHV-1 PROTEIN ICP0
RP   (MICROBIAL INFECTION).
RX   PubMed=34759314; DOI=10.1038/s41586-021-04054-5;
RA   Gaidt M.M., Morrow A., Fairgrieve M.R., Karr J.P., Yosef N., Vance R.E.;
RT   "Self-guarding of MORC3 enables virulence factor-triggered immunity.";
RL   Nature 600:138-142(2021).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 400-460 IN COMPLEX WITH THE AMINO
RP   TERMINUS OF HISTONE H3, FUNCTION, AND DOMAIN CW-TYPE ZINC FINGER.
RX   PubMed=26933034; DOI=10.1074/jbc.m116.718973;
RA   Liu Y., Tempel W., Zhang Q., Liang X., Loppnau P., Qin S., Min J.;
RT   "Family-wide Characterization of Histone Binding Abilities of Human CW
RT   Domain-containing Proteins.";
RL   J. Biol. Chem. 291:9000-9013(2016).
RN   [20] {ECO:0007744|PDB:6O1E}
RP   X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 1-455, ACTIVITY REGULATION,
RP   SUBUNIT, AND MUTAGENESIS OF TRP-419.
RX   PubMed=30850548; DOI=10.1073/pnas.1819524116;
RA   Zhang Y., Klein B.J., Cox K.L., Bertulat B., Tencer A.H., Holden M.R.,
RA   Wright G.M., Black J., Cardoso M.C., Poirier M.G., Kutateladze T.G.;
RT   "Mechanism for autoinhibition and activation of the MORC3 ATPase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 116:6111-6119(2019).
RN   [21] {ECO:0007744|PDB:6O5W}
RP   X-RAY CRYSTALLOGRAPHY (1.41 ANGSTROMS) OF 407-455, INTERACTION WITH
RP   INFLUENZA VIRUS PROTEIN NS1 (MICROBIAL INFECTION), AND MUTAGENESIS OF
RP   ASP-67 AND GLU-431.
RX   PubMed=31006586; DOI=10.1016/j.str.2019.03.015;
RA   Zhang Y., Ahn J., Green K.J., Vann K.R., Black J., Brooke C.B.,
RA   Kutateladze T.G.;
RT   "MORC3 Is a Target of the Influenza A Viral Protein NS1.";
RL   Structure 27:1029-1033.e3(2019).
CC   -!- FUNCTION: Nuclear matrix protein which forms MORC3-NBs (nuclear bodies)
CC       via an ATP-dependent mechanism and plays a role in innate immunity by
CC       restricting different viruses through modulation of the IFN response
CC       (PubMed:27440897, PubMed:34759314). Mechanistically, possesses a
CC       primary antiviral function through a MORC3-regulated element that
CC       activates IFNB1, and this function is guarded by a secondary IFN-
CC       repressing function (PubMed:34759314). Sumoylated MORC3-NBs associates
CC       with PML-NBs and recruits TP53 and SP100, thus regulating TP53 activity
CC       (PubMed:17332504, PubMed:20501696). Binds RNA in vitro
CC       (PubMed:11927593). Histone methylation reader which binds to non-
CC       methylated (H3K4me0), monomethylated (H3K4me1), dimethylated (H3K4me2)
CC       and trimethylated (H3K4me3) 'Lys-4' on histone H3 (PubMed:26933034).
CC       The order of binding preference is H3K4me3 > H3K4me2 > H3K4me1 >
CC       H3K4me0 (PubMed:26933034). {ECO:0000269|PubMed:11927593,
CC       ECO:0000269|PubMed:17332504, ECO:0000269|PubMed:20501696,
CC       ECO:0000269|PubMed:26933034, ECO:0000269|PubMed:27440897,
CC       ECO:0000269|PubMed:34759314}.
CC   -!- FUNCTION: (Microbial infection) May be required for influenza A
CC       transcription during viral infection (PubMed:26202233).
CC       {ECO:0000269|PubMed:26202233}.
CC   -!- ACTIVITY REGULATION: Dimerization of the ATPase domain is strictly
CC       required for the catalytic activity and binding to double-stranded DNA.
CC       Disrupting the interface between ATPase and the CW domains releases
CC       autoinhibition since the CW domain sterically impedes binding of the
CC       ATPase domain to DNA. {ECO:0000269|PubMed:30850548}.
CC   -!- SUBUNIT: Homodimer (PubMed:17332504, PubMed:30850548). The sumoylated
CC       form interacts with PML (via SUMO-interacting motif) (PubMed:17332504,
CC       PubMed:20501696). Interacts with TP53 (PubMed:17332504).
CC       {ECO:0000269|PubMed:17332504, ECO:0000269|PubMed:20501696,
CC       ECO:0000269|PubMed:30850548}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with influenza A virus PA and
CC       PB1 polymerase subunits during infection (PubMed:26202233). Interacts
CC       (via CW domain) with influenza A protein NS1 (PubMed:31006586).
CC       {ECO:0000269|PubMed:26202233, ECO:0000269|PubMed:31006586}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus
CC       1/HHV-1 protein ICP0; this interaction mediates MORC3 degradation,
CC       which leads to de-repression of a MORC3-regulated DNA element (MRE)
CC       adjacent to the IFNB1 locus. {ECO:0000269|PubMed:27440897,
CC       ECO:0000269|PubMed:34759314}.
CC   -!- INTERACTION:
CC       Q14149; P63167: DYNLL1; NbExp=5; IntAct=EBI-2556145, EBI-349105;
CC       Q14149; Q9NWF9: RNF216; NbExp=3; IntAct=EBI-2556145, EBI-723313;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:11927593, ECO:0000269|PubMed:17332504}. Nucleus
CC       matrix {ECO:0000269|PubMed:11927593, ECO:0000269|PubMed:20501696}.
CC       Nucleus, PML body {ECO:0000269|PubMed:17332504,
CC       ECO:0000269|PubMed:27440897}. Chromosome
CC       {ECO:0000250|UniProtKB:F7BJB9}. Note=Also found in PML-independent
CC       nuclear bodies. Localization to nuclear bodies is ATP-dependent.
CC       {ECO:0000269|PubMed:20501696}.
CC   -!- TISSUE SPECIFICITY: Expressed in heart, placenta, skeletal muscle,
CC       brain, pancreas, lung, liver, but not kidney.
CC       {ECO:0000269|PubMed:11927593}.
CC   -!- DOMAIN: The CW-TYPE zinc finger mediates its binding to trimethylated
CC       histone H3K4me3. {ECO:0000269|PubMed:26933034}.
CC   -!- PTM: Sumoylation is involved in interaction with PML and localization
CC       to PML nuclear bodies. {ECO:0000269|PubMed:20501696}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA09485.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAA89432.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D50926; BAA09485.2; ALT_INIT; mRNA.
DR   EMBL; AK292957; BAF85646.1; -; mRNA.
DR   EMBL; AP000693; BAA89432.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AP000692; BAA89432.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS42924.1; -.
DR   RefSeq; NP_056173.1; NM_015358.3.
DR   PDB; 4QQ4; X-ray; 1.75 A; A/B=400-460.
DR   PDB; 5SVI; X-ray; 1.61 A; A=407-453.
DR   PDB; 5SVX; X-ray; 1.56 A; A=407-454.
DR   PDB; 5SVY; X-ray; 1.05 A; A=407-455.
DR   PDB; 6O1E; X-ray; 2.41 A; A=1-455.
DR   PDB; 6O5W; X-ray; 1.41 A; A=407-455.
DR   PDBsum; 4QQ4; -.
DR   PDBsum; 5SVI; -.
DR   PDBsum; 5SVX; -.
DR   PDBsum; 5SVY; -.
DR   PDBsum; 6O1E; -.
DR   PDBsum; 6O5W; -.
DR   AlphaFoldDB; Q14149; -.
DR   SMR; Q14149; -.
DR   BioGRID; 117062; 81.
DR   FunCoup; Q14149; 3596.
DR   IntAct; Q14149; 54.
DR   MINT; Q14149; -.
DR   STRING; 9606.ENSP00000383333; -.
DR   GlyCosmos; Q14149; 1 site, 1 glycan.
DR   GlyGen; Q14149; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q14149; -.
DR   PhosphoSitePlus; Q14149; -.
DR   BioMuta; MORC3; -.
DR   DMDM; 108935853; -.
DR   jPOST; Q14149; -.
DR   MassIVE; Q14149; -.
DR   PaxDb; 9606-ENSP00000383333; -.
DR   PeptideAtlas; Q14149; -.
DR   ProteomicsDB; 59852; -.
DR   Pumba; Q14149; -.
DR   Antibodypedia; 5016; 90 antibodies from 22 providers.
DR   DNASU; 23515; -.
DR   Ensembl; ENST00000400485.6; ENSP00000383333.1; ENSG00000159256.13.
DR   GeneID; 23515; -.
DR   KEGG; hsa:23515; -.
DR   MANE-Select; ENST00000400485.6; ENSP00000383333.1; NM_015358.3; NP_056173.1.
DR   UCSC; uc002yvi.3; human.
DR   AGR; HGNC:23572; -.
DR   CTD; 23515; -.
DR   DisGeNET; 23515; -.
DR   GeneCards; MORC3; -.
DR   HGNC; HGNC:23572; MORC3.
DR   HPA; ENSG00000159256; Low tissue specificity.
DR   MIM; 610078; gene.
DR   OpenTargets; ENSG00000159256; -.
DR   VEuPathDB; HostDB:ENSG00000159256; -.
DR   eggNOG; KOG1845; Eukaryota.
DR   GeneTree; ENSGT00940000160495; -.
DR   HOGENOM; CLU_011516_2_0_1; -.
DR   InParanoid; Q14149; -.
DR   OMA; IPYEKTH; -.
DR   OrthoDB; 757982at2759; -.
DR   PAN-GO; Q14149; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q14149; -.
DR   PathwayCommons; Q14149; -.
DR   SignaLink; Q14149; -.
DR   BioGRID-ORCS; 23515; 12 hits in 1165 CRISPR screens.
DR   CD-CODE; 353F5E6C; MORC3 nuclear body.
DR   CD-CODE; B5B9A610; PML body.
DR   ChiTaRS; MORC3; human.
DR   EvolutionaryTrace; Q14149; -.
DR   GeneWiki; MORC3; -.
DR   GenomeRNAi; 23515; -.
DR   Pharos; Q14149; Tbio.
DR   PRO; PR:Q14149; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   RNAct; Q14149; protein.
DR   Bgee; ENSG00000159256; Expressed in calcaneal tendon and 197 other cell types or tissues.
DR   ExpressionAtlas; Q14149; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IDA:UniProt.
DR   GO; GO:0016363; C:nuclear matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0016605; C:PML body; IDA:MGI.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProt.
DR   GO; GO:0140002; F:histone H3K4me3 reader activity; IDA:UniProtKB.
DR   GO; GO:0035064; F:methylated histone binding; IBA:GO_Central.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt.
DR   GO; GO:0051457; P:maintenance of protein location in nucleus; IDA:MGI.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IDA:MGI.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:UniProt.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProt.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:MGI.
DR   GO; GO:2000774; P:positive regulation of cellular senescence; IDA:MGI.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0050821; P:protein stabilization; IDA:MGI.
DR   CDD; cd16931; HATPase_MORC-like; 1.
DR   FunFam; 3.30.40.100:FF:000003; MORC family CW-type zinc finger 3; 1.
DR   FunFam; 3.30.565.10:FF:000035; MORC family CW-type zinc finger protein 4; 1.
DR   Gene3D; 3.30.40.100; -; 1.
DR   Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1.
DR   InterPro; IPR036890; HATPase_C_sf.
DR   InterPro; IPR045261; MORC_ATPase.
DR   InterPro; IPR041006; Morc_S5.
DR   InterPro; IPR011124; Znf_CW.
DR   PANTHER; PTHR23336:SF17; MORC FAMILY CW-TYPE ZINC FINGER PROTEIN 3; 1.
DR   PANTHER; PTHR23336; ZINC FINGER CW-TYPE COILED-COIL DOMAIN PROTEIN 3; 1.
DR   Pfam; PF13589; HATPase_c_3; 1.
DR   Pfam; PF17942; Morc6_S5; 1.
DR   Pfam; PF07496; zf-CW; 1.
DR   SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1.
DR   PROSITE; PS51050; ZF_CW; 1.
DR   neXtProt; NX_Q14149; -.
DR   PharmGKB; PA128394632; -.
DR   TreeFam; TF329118; -.
PE   1: Evidence at protein level;
KW   3D-structure; Chromosome; Coiled coil; Host-virus interaction; Immunity;
KW   Innate immunity; Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; RNA-binding;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..939
FT                   /note="MORC family CW-type zinc finger protein 3"
FT                   /id="PRO_0000096538"
FT   ZN_FING         404..454
FT                   /note="CW-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00454"
FT   REGION          326..353
FT                   /note="Nuclear matrix binding"
FT                   /evidence="ECO:0000269|PubMed:11927593"
FT   REGION          500..591
FT                   /note="RNA binding"
FT                   /evidence="ECO:0000269|PubMed:11927593"
FT   REGION          524..545
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          613..640
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          686..877
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        524..539
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        631..640
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         413
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00454"
FT   BINDING         416
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00454"
FT   BINDING         435
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00454"
FT   BINDING         446
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00454"
FT   MOD_RES         503
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         514
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         540
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         560
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         765
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        191
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        205
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        231
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        280
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        293
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        555
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        597
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   CROSSLNK        597
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        650
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   CROSSLNK        650
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        651
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   CROSSLNK        651
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        740
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   CROSSLNK        740
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        794
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   CROSSLNK        794
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        855
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   MUTAGEN         35
FT                   /note="E->A: Fails to localize to PML nuclear bodies and
FT                   activate TP53."
FT                   /evidence="ECO:0000269|PubMed:17332504"
FT   MUTAGEN         67
FT                   /note="D->N: Forms nuclear bodies, but rapidly diffuses
FT                   throughout the nucleus under conditions of ATP depletion."
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   MUTAGEN         101
FT                   /note="G->A: Diffuse nuclear localization. Fails to form
FT                   nuclear bodies in the presence of ATP."
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   MUTAGEN         419
FT                   /note="W->A: About threefold increase in catalytic
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:30850548"
FT   MUTAGEN         419
FT                   /note="W->A: Diffuse nuclear localization, possibly due to
FT                   loss of DNA or nucleosome binding."
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   MUTAGEN         431
FT                   /note="E->A: Strong decrease of binding to NS1."
FT                   /evidence="ECO:0000269|PubMed:31006586"
FT   MUTAGEN         597
FT                   /note="K->R: Loss of sumoylation; when associated with
FT                   R-650; R-651; R-740 and R-794."
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   MUTAGEN         650
FT                   /note="K->R: Loss of sumoylation; when associated with
FT                   R-597; R-651; R-740 and R-794."
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   MUTAGEN         651
FT                   /note="K->R: Loss of sumoylation; when associated with
FT                   R-597; R-650; R-740 and R-794."
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   MUTAGEN         740
FT                   /note="K->R: Loss of sumoylation; when associated with
FT                   R-597; R-650; R-651 and R-794."
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   MUTAGEN         794
FT                   /note="K->R: Loss of sumoylation; when associated with
FT                   R-597; R-650; R-651 and R-740."
FT                   /evidence="ECO:0000269|PubMed:20501696"
FT   HELIX           17..23
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           29..41
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   TURN            43..45
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          48..57
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          60..67
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           74..80
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          82..84
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           103..111
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          112..123
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          125..131
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           132..137
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          147..150
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           159..172
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           178..187
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          190..201
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          203..211
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           246..248
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           251..257
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          258..261
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          264..268
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           278..280
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          283..290
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          295..297
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          299..305
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          314..319
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          322..328
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           332..335
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          343..348
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   TURN            356..359
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           365..389
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   TURN            390..392
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   HELIX           399..401
FT                   /evidence="ECO:0007829|PDB:6O1E"
FT   STRAND          408..412
FT                   /evidence="ECO:0007829|PDB:5SVY"
FT   TURN            414..416
FT                   /evidence="ECO:0007829|PDB:5SVY"
FT   STRAND          419..422
FT                   /evidence="ECO:0007829|PDB:5SVY"
FT   HELIX           435..437
FT                   /evidence="ECO:0007829|PDB:5SVY"
FT   HELIX           441..443
FT                   /evidence="ECO:0007829|PDB:5SVY"
SQ   SEQUENCE   939 AA;  107113 MW;  7DF0EC31936BF5FF CRC64;
     MAAQPPRGIR LSALCPKFLH TNSTSHTWPF SAVAELIDNA YDPDVNAKQI WIDKTVINDH
     ICLTFTDNGN GMTSDKLHKM LSFGFSDKVT MNGHVPVGLY GNGFKSGSMR LGKDAIVFTK
     NGESMSVGLL SQTYLEVIKA EHVVVPIVAF NKHRQMINLA ESKASLAAIL EHSLFSTEQK
     LLAELDAIIG KKGTRIIIWN LRSYKNATEF DFEKDKYDIR IPEDLDEITG KKGYKKQERM
     DQIAPESDYS LRAYCSILYL KPRMQIILRG QKVKTQLVSK SLAYIERDVY RPKFLSKTVR
     ITFGFNCRNK DHYGIMMYHR NRLIKAYEKV GCQLRANNMG VGVVGIIECN FLKPTHNKQD
     FDYTNEYRLT ITALGEKLND YWNEMKVKKN TEYPLNLPVE DIQKRPDQTW VQCDACLKWR
     KLPDGMDQLP EKWYCSNNPD PQFRNCEVPE EPEDEDLVHP TYEKTYKKTN KEKFRIRQPE
     MIPRINAELL FRPTALSTPS FSSPKESVPR RHLSEGTNSY ATRLLNNHQV PPQSEPESNS
     LKRRLSTRSS ILNAKNRRLS SQFENSVYKG DDDDEDVIIL EENSTPKPAV DHDIDMKSEQ
     SHVEQGGVQV EFVGDSEPCG QTGSTSTSSS RCDQGNTAAT QTEVPSLVVK KEETVEDEID
     VRNDAVILPS CVEAEAKIHE TQETTDKSAD DAGCQLQELR NQLLLVTEEK ENYKRQCHMF
     TDQIKVLQQR ILEMNDKYVK KETCHQSTET DAVFLLESIN GKSESPDHMV SQYQQALEEI
     ERLKKQCSAL QHVKAECSQC SNNESKSEMD EMAVQLDDVF RQLDKCSIER DQYKSEVELL
     EMEKSQIRSQ CEELKTEVEQ LKSTNQQTAT DVSTSSNIEE SVNHMDGESL KLRSLRVNVG
     QLLAMIVPDL DLQQVNYDVD VVDEILGQVV EQMSEISST
//
